OrbiMed is a healthcare-focused investment firm based in New York, founded in 1989, with approximately $5 billion in assets under management. It engages in private equity, venture capital, and growth investments across the global healthcare landscape, spanning biopharmaceuticals, biotechnology, life sciences tools, medical devices, diagnostics, health care services, and digital health. The firm invests across the development spectrum, from startup ventures to mature companies, and pursues opportunities worldwide, including North America, Europe, Asia, Israel and India, leveraging a long-standing specialization in the sector. Through its diversified capital programs, OrbiMed partners with management to advance innovative therapies, tools, and services that address significant medical needs.

RA Capital Management is a Boston-based investment firm that specializes in life sciences and healthcare companies. The firm provides investment management and venture capital services, backing companies developing drugs, medical devices, diagnostics, and biotech tools. Its team combines expertise in biology, chemistry, and medicine with industry and business development experience. RA Capital supports companies across multiple stages, from seed funding to growth financings, including private and public rounds, and often takes board seats and seeks co-investment opportunities. Through its activity, it aims to identify technologies with potential to advance prevention and treatment, genetic testing and personalized medicine, and other patient-focused innovations.

Eli Lilly is a global pharmaceutical company that discovers, develops, manufactures, and sells medicines across neuroscience, cardiometabolic diseases, cancer, and immunology. It operates manufacturing and research facilities in the United States, Puerto Rico, and about 25 other countries, with products sold in roughly 135 countries. The portfolio includes Verzenio, Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, Humulin, Taltz, and Olumiant, reflecting a diversified, science‑driven approach. In addition to human medicines, Lilly conducts research in animal health to treat animal diseases and support agricultural productivity. The company maintains a strong emphasis on research and development to address unmet medical needs and to bring innovative therapies to patients worldwide.

Novo Nordisk is a global healthcare company that develops, manufactures, and distributes insulin and other diabetes medicines to treat chronic diseases. It pursues scientific breakthroughs and aims to expand access to its medicines, with the ultimate goal of preventing and curing disease.

SOSV is a global venture capital firm based in Princeton, New Jersey, founded in 1995, that focuses on seed to growth investments in deep technology across health, environmental tech, hardware, robotics, and cross border software, with a particular emphasis on Asia. The company runs accelerator style startup development programs, including HAX and IndieBio, which provide facilities, engineering resources, and lab equipment to help founders accelerate product development, acquire customers, and attract later stage funding. SOSV pursues a limited number of high potential startups, offering extensive hands on support to speed commercialization and scale, and aims to back innovations that improve human and planetary health.

Alexandria Venture Investments is the strategic venture capital arm of Alexandria Real Estate Equities. It provides seed through growth capital to life science and technology companies developing breakthrough therapies, diagnostics, research tools, agrifoodtech, agtech, digital health, and related platforms. Backed by the parent company’s industry experience and scientific advisory network, the firm leverages long-standing relationships and domain expertise to support early to growth-stage ventures aiming to translate scientific advances into practical healthcare and technology solutions.

Morningside is a Boston-based investment firm founded in 1986 as a family office for the Chan family. It makes venture capital investments in companies with novel science and technology, with deep expertise in life sciences, digital health, artificial intelligence, materials, and technology. The firm takes a long-term approach to building companies and emphasizes ethical conduct. In addition to its investment activities, Morningside supports charitable initiatives in education, research and healthcare, including collaborations with Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and based in San Francisco, with offices in Canada, the United States and Europe. The firm invests across the healthcare sector at all stages, with an emphasis on discovery and development of novel therapeutics, and portfolios spanning biotechnology, pharmaceuticals, life sciences, healthcare devices and healthtech. Versant combines deep investment, operating and scientific expertise to support entrepreneurs through hands-on company building. It has backed more than 65 portfolio companies that have achieved acquisitions or IPOs.

Qiming Venture Partners is a China-based venture capital firm founded in 2006, with offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore. It manages USD and RMB funds totaling about 9.5 billion in capital and backs early- and growth-stage technology, consumer, and healthcare companies. The firm has backed more than 530 portfolio companies, with over 200 exits via IPOs or M&A, and more than 70 unicorn or super unicorn companies.

New Enterprise Associates is a U.S.-based venture capital firm founded in 1977 and headquartered in Menlo Park, California. It invests in technology and healthcare companies across stages and geographies, supporting startups from seed to growth. The firm operates globally with investments in the United States, Asia, and Brazil among others, and has a long track record of portfolio IPOs and acquisitions. It has over $19 billion in cumulative committed capital.

Established in 2020, the European Innovation Council supports innovative startups and researchers with promising ideas, focusing on early-stage companies with positive environmental, social, or governance impacts. It co-invests alongside private investors.

ARCH Venture Partners is a United States-based venture capital firm founded in 1986 and headquartered in Chicago, Illinois. The firm focuses on science-driven companies, with a track record of commercializing technologies developed at academic research institutions and national laboratories. It primarily invests in life sciences, biotechnology, pharmaceuticals, healthcare technology, and related sectors, and also backs software, materials, clean tech, and information technology across early to growth stages. ARCH emphasizes relationships with scientists and entrepreneurs, often taking early stakes and supporting subsequent rounds to help market entry and scale. The firm has raised multiple venture funds totaling several billion dollars and maintains a national and international reach with offices across North America.

Samsara BioCapital is a Palo Alto-based venture capital firm founded in 2016 that focuses on the healthcare sector, including biotechnology, pharmaceuticals, oncology, and life sciences. The firm seeks opportunities in the United States and provides investment advisory services as part of its activities, supporting companies developing innovative therapies and related technologies.

Venrock is a Palo Alto-based venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It concentrates on seed and early-stage technology and healthcare investments and has backed landmark companies such as Apple Computer, Intel, Illumina, Gilead Sciences, Athenahealth, DoubleClick, Nest, SlideShare, and Tudou. The firm manages multiple funds and maintains a US-focused investment approach, supporting entrepreneurs across information technology, life sciences, and related sectors throughout their growth journey.

Pfizer is a global pharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines across a broad range of therapeutic areas. It maintains an extensive portfolio of prescription drugs and vaccines, with notable products such as Prevnar 13, Ibrance, and Eliquis. The company serves customers worldwide, with substantial international and emerging-market sales. Through ongoing research and development, Pfizer pursues new treatments to address major diseases, including cancer and neurodegenerative conditions, and aims to improve patient outcomes by delivering safe, effective, and accessible therapies. Founded in 1849 and headquartered in the United States, Pfizer operates globally to advance health care through science, partnerships, and scalable manufacturing capabilities.

Polaris Partners is a Boston-based venture capital firm with offices in Boston and San Francisco that backs technology and life sciences companies across the United States and Europe. Founded in 1996, the firm partners with repeat entrepreneurs to support companies through multiple stages, from inception to growth, with a focus on software, healthcare information technology, digital health, life sciences, biotechnology, pharmaceuticals, genomics, and related sectors. Its investments span the business-to-business and business-to-consumer markets, software as a service, and other technology-enabled solutions, aiming to build durable platform companies and address significant needs in healthcare and technology.

Mission BioCapital is a life science venture capital firm that backs early‑stage biotechnology companies. Based in Cambridge, Massachusetts, the firm draws on a leadership team with a long history of investing in and launching numerous early‑stage life science ventures. It operates in regions with strong research, discovery, and venture capital ecosystems and is known for providing deep expertise and active support to its portfolio companies.

Redmile Group is a San Francisco-based private equity firm with an office in New York that focuses on investments in the healthcare sector, pursuing opportunities across venture, growth, and crossover stages to support healthcare companies with strategic capital and partnerships.

Vivo Capital is a healthcare-focused investment firm founded in 1996 and headquartered in Palo Alto, California, with offices in Asia. The firm operates a multi-strategy platform including growth equity, private equity, venture capital, and public equity, and invests across biopharmaceuticals, specialty pharmaceuticals, medical devices, diagnostics, and healthcare services. It pursues opportunities globally, including the United States and China, and has invested in more than 290 companies. The team comprises physicians, scientists, entrepreneurs, operating executives, and industry experts, and the firm manages about $5.8 billion in assets.

Sofinnova Partners is an independent venture capital firm based in Paris, France, focusing on life sciences from seed to later-stage investments. It backs startups, early-stage companies, corporate spin-offs and occasionally turnaround situations in biopharmaceuticals/biotech, medical devices, and industrial biotechnology. The firm typically takes a lead or cornerstone role, often serving as the first institutional investor in Series A rounds, and actively supports portfolio companies through formation and beyond, including board participation. The firm manages more than €2 billion in life sciences assets.

Deerfield Management is a New York-based investment management firm founded in 1994 that focuses on healthcare. It engages in long-term structured investments in both public and private healthcare companies, and operates across investment activities, information services, and philanthropy. It acts as an investment adviser and supports private and public investments across life sciences, medical devices, diagnostics, digital health, and health services.

Atlas Venture is a Cambridge, Massachusetts–based venture capital firm founded in 1980 that specializes in life sciences and technology. It pursues seed-led venture creation and early-stage investments to build scalable companies in biopharmaceuticals, diagnostics, medical devices, and related biomedical technologies, as well as software and other technology sectors. The firm often leads investments and seeks board representation to support portfolio companies as they grow toward acquisition or public offerings. Atlas operates with dedicated life sciences and technology teams and maintains an international footprint across the United States and Europe.

F-Prime Capital is a venture capital investment firm based in Cambridge, Massachusetts. Founded in 1969 with roots in Fidelity Investments, it backs entrepreneurs across technology and life sciences, investing in sectors such as crypto, enterprise information technology, fintech, frontier technologies, health information technology and services, medtech and therapeutics, with a global reach across the Americas, Europe and Asia.

Forbion is a Netherlands-based venture capital firm focusing on life sciences and bioeconomy companies across Europe and North America. It invests in a broad spectrum of sectors including pharmaceuticals, biotechnology, MedTech, autoimmune and inflammatory diseases, cardiovascular and metabolic disorders, CNS conditions, oncology, ophthalmology, orphan and rare diseases, and related environmental, food, and materials technologies. The firm pursues both early-stage and growth investments in life sciences and technology companies, providing capital and strategic support to advance drug development, medical devices, and other innovations in health and bioscience.

Logos Capital is a hedge fund manager based in San Francisco, founded in 2019, specializing in fundamental biotechnology investments. The firm combines in-house data analytics with scientific and clinical expertise to rigorously evaluate potential therapies and treatment platforms. It uses fundamental and sector-focused equity strategies and applies statistical modeling of clinical data to strengthen diligence and identify compelling opportunities with the aim of delivering uncorrelated returns. By integrating medical, scientific, and statistical perspectives, Logos Capital seeks to deepen its conviction in investment ideas and maintain disciplined risk management.

Omega Funds is a Boston-based venture capital firm that backs life sciences, biotechnology, health care technology and related software-enabled solutions. Founded in 2004, the firm invests across the United States and Europe, targeting pharmaceuticals, biotechnology, oncology, immunology, rare diseases, precision medicine, digital health, healthtech and cybersecurity. It manages multiple funds, including Omega Fund IV, V, VI and VII, and supports companies from early to growth stages. The firm serves as an investment adviser to its funds and seeks to build a diversified portfolio at the intersection of science and technology.

EcoR1 Capital is a San Francisco-based investment firm focused on the biotechnology sector. Founded in 2012, the company operates as an investment adviser and venture investor, seeking to identify and support innovative therapeutic solutions with the potential to improve patient outcomes. It provides investment services to pooled vehicles and participates in biotech investments across private and public markets, reflecting a commitment to advancing medical research.

The Column Group is a venture capital firm focused on building the next generation of biotechnology companies. Based in San Francisco, California, the firm invests in seed- and early-stage biotechnology, life sciences, and technology-driven startups in the United States, with a particular emphasis on oncology and drug discovery. It supports companies developing new therapies and scientific platforms aimed at unmet medical needs, pursuing a long-term approach to enable multiple product opportunities rather than quick exits. Its portfolio interests include cancer, inflammation, infectious disease, metabolic and cardiovascular disorders, and nervous system diseases, reflecting a focus on translating science into therapeutics.

Sofinnova Investments is a venture capital firm founded in 1976 and headquartered in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It backs life sciences and information technology companies across the United States and Europe, from seed through early and growth stages. In life sciences, it targets clinical-stage pharmaceutical and biotechnology companies, drug discovery platforms, and medical technology addressing diseases with unmet medical needs, including oncology, respiratory, dermatology, ophthalmology, neurology and women's health. In information technology, it supports product-oriented software, enterprise IT solutions and telecommunications infrastructure. The firm often requires board participation for early-stage lead or co-lead investments and emphasizes hands-on guidance to help entrepreneurs build global businesses.

SR One Capital Management is the corporate venture capital arm of GlaxoSmithKline. Based in Redwood City, California, the firm, founded in 1985, makes global venture investments in life sciences, including biotechnology, healthcare, medical devices, and related information technology, seeking innovative science with potential to significantly improve medical care. As a registered investment adviser, it supports early- and growth-stage companies aligned with GlaxoSmithKline's scientific priorities and advances medical innovation.

Casdin Capital is a New York-based investment firm focused on life sciences and healthcare. Founded in 2012 by Eli Casdin, the firm pursues private investments and research-driven opportunities across early- to late-stage companies in these sectors and is described as a venture capital firm and a registered investment adviser.

SV Health Investors is a United States‑headquartered healthcare and life sciences venture capital and growth equity firm. Formerly known as SV Life Sciences, it supports entrepreneurs who create breakthrough companies and treatments across biotech, medical devices, and healthcare services. With offices in Boston, San Francisco and London, the firm has over two billion dollars of capital under management across seven private healthcare funds and more than two decades of activity in the US and Europe.

Deep Track Capital is a venture capital investment firm focused on life sciences and biotechnology, headquartered in Greenwich, Connecticut. Founded in 2020, the firm partners with management teams of innovative public and pre-IPO biotechnology companies, providing capital, time, expertise, and an extensive network to support growth. It seeks to lead transactions, build large syndicates, and participate in rounds led by other qualified investors, aiming to create value through strategic guidance and collaborative partnerships rather than simple financing.

Takeda is a global pharmaceutical company, and Japan's largest drug maker, focused on researching, developing, manufacturing, marketing and distributing prescription medicines and related therapies. Its core therapeutic areas include oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which together account for the majority of revenue. The company operates globally with a diversified geographic mix, deriving more than half of sales from the United States, about 20% from Japan, and about 20% from Europe and Canada. Takeda pursues innovation across drug discovery and development, maintains a portfolio spanning pharmaceuticals and biologics, and emphasizes patient-centric care and collaboration with researchers to advance clinical proof concepts and address unmet medical needs.

HBM Healthcare Investments is a Switzerland-based investment firm founded in 2001 and based in Zug. It concentrates on the healthcare sector, spanning human medicine, biotechnology, medical technology and diagnostics. The firm maintains a diversified portfolio that includes private companies, public companies, funds, cash and other assets, reflecting exposure across different stages and sectors within healthcare.

Khosla Ventures is a California-based venture capital firm founded in 2004 by Vinod Khosla. The firm backs entrepreneurs with venture assistance, strategic guidance, and capital, focusing on bold, early-stage technology companies. It invests across sectors including AI, climate and sustainability, enterprise software, consumer technologies, fintech, digital health, medtech and diagnostics, therapeutics, and frontier technologies. Based in Menlo Park, the firm manages several funds to support startups across stages, prioritizing ventures that address large markets and have potential for significant social and economic impact.

MPM Capital is a healthcare investment firm that finances biotechnology, life sciences, and medical technologies with the aim of translating science into clinical outcomes. The firm backs companies across stages from seed through late venture and growth, including oncology, medical devices, specialty pharma, and diagnostics, with investments typically spanning global opportunities in the United States, Europe, and Asia. It often serves as a lead investor and may take interim operating roles to support portfolio companies, leveraging a three-decade track record in building biotechnology and healthcare companies.

IP Group is a London-based venture capital firm that focuses on commercialising intellectual property from research-intensive institutions. It creates value by identifying early-stage IP, developing it into commercially viable opportunities, and forming strategic partnerships to support portfolio companies. The firm provides capital, strategic guidance, and industry insight to science- and technology-based businesses, with emphasis on clean technology, life sciences, and deep tech. With more than twenty years of experience, IP Group supports the growth of science and technology companies from inception toward scale, helping translate research into market-ready products and accelerate their impact.

Nextech Invest is a Zurich-based venture capital firm that targets early-stage healthcare and life sciences companies worldwide, with a particular focus on oncology, therapeutics, drug discovery, biotechnology, and information technology. The firm backs startups through early to emerging growth stages and supports co-investments, often seeking a board seat in portfolio companies. It operates across Europe and the United States, with an emphasis on interdisciplinary projects and technologies spanning therapies, diagnostics, medical devices, and enabling platforms. Founded in 1998, Nextech Invest maintains international reach through offices in Zurich and Newton, United States, and maintains an active network of scientific advisers and industry partners to guide investments. The firm pursues strategic exits within a few years via sale or other transactions and positions itself as an independent investor aligned with life science and tech-driven healthcare innovations.

Kurma Partners is a Paris-based investment management company focused on funding innovation in healthcare and biotechnology across Europe. Established in 2009, it targets early-stage to development capital for life sciences companies and digital health ventures, spanning healthcare, biotechnology, and related technology sectors. The firm pursues a hands-on approach to support research-driven startups, leveraging connections with research institutes and hospitals to advance therapeutic and medical innovations. Through its activity as a private equity and venture investor, Kurma Partners seeks to back companies throughout their growth trajectory, from initial concept to market readiness, helping them navigate clinical development, regulatory pathways, and commercialization in the European market.

Boxer Capital is the venture capital arm of Tavistock Group, based in San Diego, California. It invests in public and private biotechnology and life sciences companies across the drug development lifecycle, from early preclinical discovery to late-stage clinical and commercial assets. Founded in 2005, Boxer Capital focuses on biotechnology drug development opportunities.

Third Rock Ventures is a Boston-based venture capital firm focused on investing in life sciences and healthcare companies in the United States. It backs startups developing medicines, diagnostics, medical devices, and related technologies with high growth potential, often providing substantial initial capital and strategic collaborations to advance development. The firm takes an active role in portfolio companies, frequently leading investment rounds and sometimes assuming key management positions, and collaborates with larger pharmaceutical and biotechnology companies. Since its founding in 2007, Third Rock has supported firms across biotechnology, therapeutics, oncology, medical devices, and data-driven life sciences, aiming to bring transformational healthcare innovations to market. The firm operates primarily from Boston with additional presence in San Francisco.

Canaan Partners is a San Francisco-based venture capital firm founded in 1987 that operates globally with offices in Israel and India. It focuses on early-stage investments in technology and healthcare, including software, fintech, enterprise/cloud, marketplaces, digital health, biopharma, and medtech, and it has a history of backing startups that achieve exits.

TCG Crossover, also known as TCG X, is a healthcare-focused investment firm that backs companies developing disruptive medicines to improve patient outcomes. It invests in both private and public biotech companies led by entrepreneurial teams and operates with offices in Palo Alto and New York City. Founded in 2020, the firm focuses on opportunities in the United States and Europe, with emphasis on drug discovery and medicine sectors.

Longitude Capital is a private equity and venture capital firm specializing in life sciences, including pharmaceuticals, biotechnology, medical devices, and related tools and services. Founded in 2006 and headquartered in Menlo Park, California, with offices in Greenwich, Connecticut and Boston, it targets investments in US-based and international life science companies at startup through growth stages. The firm pursues venture growth opportunities in therapeutics, genomics, drug development, medical technology, R&D tools, diagnostics, and related health sectors. It backs both privately held and publicly traded companies and employs a range of structures including traditional venture investments, asset spin-outs, recapitalizations, PIPEs, royalties, and other equity-linked instruments. Longitude Capital seeks clinically de-risked assets with favorable risk-return profiles, aiming for exit within roughly three to five years and often taking lead or co-lead roles with a seat on the board. The approach emphasizes building a balanced portfolio across clinical- and commercial-stage assets to improve outcomes, reduce costs, and advance healthcare.

VenBio Partners is a California-based venture capital firm focused on life sciences and healthcare, investing across the drug discovery spectrum from early to late stages in the United States. The firm tends to lead its investments, builds syndicates, and positions portfolio companies to meet potential acquisition partners from the outset. It concentrates on preparing companies in areas such as intellectual property, chemistry, manufacturing and controls (CMC), and clinical trial design and regulatory considerations to maximize impact. Supported by an experienced team, VenBio aims to form lasting relationships with leaders in the field and help portfolio companies advance meaningful therapies.

5AM Ventures is a San Francisco-based venture capital firm founded in 2002 by John Diekman and Andrew Schwab. The firm specializes in seed- and early-stage investments in life sciences and healthcare, including biopharmaceuticals, medical technology, digital health, and research instrumentation, with activity across the United States and North America. It supports early companies through strategic financing and guidance to help advance innovative therapies and health-related technologies.

Alumni Ventures Group is a venture capital firm based in Manchester, New Hampshire, established in 2013. It targets individual accredited investors who previously had limited access to venture capital by enabling alumni from top entrepreneurial schools to invest together in ventures led by fellow alumni. The firm backs companies with an alumni connection and an institutional lead investor with sector expertise. It offers focused funds that provide accredited investors access to a diversified venture portfolio by type, sector, stage, and geography. The organization engages in seed, early-stage, and late-stage pre-IPO investments across technology, consumer, financial services, health care, life sciences, and other sectors.

High-Tech Gründerfonds is a Germany-based seed and early-stage venture capital firm focused on technology companies in Germany. Based in Bonn with an additional office in Berlin, it operates as a public-private partnership that supports high-tech startups across information technology, software, hardware, life sciences, chemistry and related fields. HTGF provides initial funding and follow-on capital to eligible young companies, often taking minority stakes and participating as lead or co-investor, while offering hands-on guidance from experienced investment managers and startup experts. Since its founding in 2005, the firm has backed numerous startups and facilitated the growth of portfolio companies through multiple funds aimed at early stages. The model combines both public support, involving government and financial institutions, with private investor participation to nurture startups from concept to market.

Hercules Capital is a specialty finance company and non-bank lender that provides venture debt and growth capital to venture-backed technology, life sciences, and sustainable/renewable technology companies at all stages. It offers senior secured loans and structured debt, often with warrants, and, to a lesser extent, equity investments, with financing tailored to fit a company’s capital plan and milestones. The firm supports portfolio companies with asset-based facilities, working capital lines, and other funding to help expand operations, accelerate product development, or pursue acquisitions and IPO readiness. Primarily serving U.S.-based firms, it leverages sector expertise, geographic reach, and a strong capital base to back companies through challenging times. The approach emphasizes flexible, customized solutions aligned to cash flow and growth trajectories.